Isomorphic Labs closes a $5 billion Series C to push AI-designed drug candidates toward clinical trials
Isomorphic Labs announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investors including a16z, continued large investment from Alphabet, and participation from all existing investors. The company says the capital will further mature its in-house drug design engine IsoDDE, expand its internal and partnered candidate pipeline, and build AI-oriented infrastructure for translational and clinical development so candidates can move into clinical trials. The company also reports positive preclinical results in internal oncology and immunology programs and in partnered projects.